Clinical Trial Update: Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

View source ↗

Summary

A completed clinical trial update notes safety signals associated with SGLT2 inhibitors in adults with type 2 diabetes, including risks of urosepsis, diabetic k…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Ketoacidosis
• Lower Extremity Amputation
• Type 2 Diabetes Mellitus
• Urosepsis

Drugs mentioned

• FARXIGA (dapagliflozin)
• INVOKANA (CANAGLIFLOZIN)
• Jardiance (empagliflozin)
• STEGLATRO (ertugliflozin)

Snippet

Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES | Conditions: Diabetes Mellitus, Type 2, Urosepsis | Status: COMPLETED